From Vishal Choudhari, PhD, and the lab of Nima Mesgarani, PhD, at Columbia University’s Zuckerman Institute: A new tech monitors the brain to detect who you are listening to. It then amplifies that voice and quiets other voices nearby. Brain surgery patients recently tested the system in hospitals. They heard two overlapping conversations, one on each side. The volunteers then tried to focus on only one conversation. One video here shows a man listening to the overlapping conversations. Researchers ask him to focus on the conversation on his right. Controlled by his brain activity, the system adjusts the volume. In another experiment, he again focuses his attention on the right. The system notices, amplifying a conversation about bread. Then, researchers ask him to switch to the left conversation. The mind reading system turns about another conversation, about repairs. In a different experience, a volunteer can freely choose what to listen to. He starts on the right. A graph appears, showing the system monitoring his brain activity. What happens when he switches from right to left? The system spots his shift in attention and adjusts the volume. Scientists asked volunteers about the experience. “In the second section, what I was listening to was louder, and the other thing was quieter. And in the first section, they were both equally loud. That’s super dope.” “I think if you could really implement it in the hearing aids, if this is the goal, I think it would be really helpful to just be able to have someone who is hard of hearing be able to kind of pinpoint exactly the conversation they want to have, especially if you’re in a location with a lot of people.” “Well I just keep thinking about about Uncle Aaron. Can you imagine if this technology existed in a world that he could access it? He might actually live a much more peaceful… life.”

“Peacemaker” immune cells could help treat diseases ranging from type 1 diabetes to neurodegeneration by restoring immune tolerance, according to a new paper in Frontiers in Science.

From cancer, diabetes and chronic infections to cardiovascular, neurodegenerative and reproductive conditions, inflammation is increasingly cited as a driver of a broad range of diseases. Immune cells called regulatory T cells (Tregs)—originally defined as “suppressor” cells that stop other immune cells from attacking the body—are being explored as “living drugs” that could eventually be adapted to target many diseases with an inflammatory component.

Such an approach, which aims to tailor Treg therapies to specific diseases and tissues, could support more precise control of immune responses. In autoimmune diseases and transplant rejection, Tregs could even help shift treatment from broad immunosuppression, which brings myriad risks, toward restored immune tolerance and longer-term disease control.

Disclaimer: Do NOT attempt without proper medical supervision.

In a paradigm-shifting breakthrough, Phase III clinical trials of DT120 — a novel, pharmaceutical-grade formulation of LSD — have demonstrated unprecedented efficacy in treating Major Depressive Disorder (MDD) following just a single dose. The study, encompassing 149 patients, revealed that a one-time administration of DT120 significantly outperformed a placebo, achieving the trial’s primary endpoint by reducing MADRS depression scores by an 8-point margin at six weeks. Remarkably, patients experienced rapid therapeutic relief within just one week, showcasing a massive 14-point advantage over the placebo group. Unlike conventional daily antidepressants that often take weeks to manifest effects, DT120 delivers profound and sustained symptom reduction from a single intervention. Hailed by Definium Therapeutics’ CEO Rob Burrow as a potential “best-in-class” therapy, these groundbreaking findings not only pave the way for expedited regulatory approval but also underscore the transformative potential of psychedelics to fundamentally revolutionize modern mental health care.

---

Definium Therapeutics has announced strong results in a phase 3 trial of its single-dosed lysergide (LSD) drug DT120 in treating adults with major depressive disorder (MDD), meeting its primary goal and all key secondary efficacy endpoints in the first trial of its kind.

The results come from the Emerge trial, a randomized, double-blind, placebo-controlled study featuring 149 participants aged 18 to 74 years enrolled across 20 sites. The participants all met specific MDD measures. They needed to have a DSM-5-confirmed diagnosis of MDD, a Montgomery-Åsberg Depression Rating Scale (MADRS) score of at least 26 and a Clinical Global Impression–Severity (CGI-S) score of at least 4 at screening and baseline.

The study examined the effectiveness of a single 100 µg dose of DT120 ODT compared with a placebo in alleviating MDD symptoms. In 2023, we covered an earlier trial of lysergide, which had shown positive results in treating general anxiety disorder (GAD).

Hundreds of genes have been linked to autism, yet the precise molecular and cellular mechanisms behind it remain largely unclear. A new study published in Nature, led by Gaia Novarino at the Institute of Science and Technology Austria (ISTA), aims to uncover these mechanisms-and in doing so, might lay the groundwork for developing medical therapies.

Autism spectrum conditions, often abbreviated as ASD in scientific and medical literature, are, for example, neurodevelopmental disorders such as epilepsy or intellectual disability. The underlying changes begin during early brain development, while the first signs often become apparent in early childhood and can persist throughout life.

A clinical trial is exploring whether high doses of vitamin B3 could give patients with glioblastoma a better chance against the aggressive brain cancer. Scientists found that niacin may help revive immune cells that tumors shut down, allowing them to attack cancer more effectively. Early results have been promising, with patients showing significantly better progression-free survival than expected.